Rallybio Corporation (NASDAQ: RLYB) and Candid Therapeutics, Inc. announced a definitive merger agreement whereby Rallybio will acquire Candid. The combined entity—operating as Candid Therapeutics, Inc.—will emerge as a global leader in T‑cell engager (TCE) therapeutics for autoimmune diseases, with a $700 million cash balance funding operations through 2030.
Transaction Overview
Item
Detail
Acquirer
Rallybio Corporation (NASDAQ: RLYB)
Target
Candid Therapeutics, Inc.
Transaction Structure
Merger
Combined Company Name
Candid Therapeutics, Inc.
Ticker Symbol
CDRX (Nasdaq)
Private Financing
> USD 505 million (oversubscribed, upsized)
Combined Cash at Closing
~ USD 700 million
Runway
Funded through 2030
Expected Closing
Mid‑2026
Candid TCE Pipeline
Asset
Target
Indication Focus
Cizutamig
BCMA TCE
Myasthenia gravis, ILD secondary to rheumatological diseases
CND261
CD20 TCE
Autoimmune diseases (B‑cell mediated)
CND319
Dual CD19/CD20 TCE
Broad B‑cell and plasma cell depletion
Portfolio
10+ indications ongoing
Spanning B‑cell and plasma cell targets
Strategic Milestones
Program
Milestone
Timeline
Cizutamig
Phase 2 initiation (myasthenia gravis)
Near‑term
Cizutamig
Phase 2 clinical readouts
2026‑2027
CND261/CND319
Multiple autoimmune indications
Through 2030
Leadership
Role
Appointment
Chairman, President, CEO
Dr. Ken Song (current Candid CEO)
Management Expertise
Autoimmune drug development, TCE biology, global clinical operations
Strategic Implications
Autoimmune TCE Leadership: The merger creates the first pure‑play autoimmune TCE company with clinical‑stage assets across 10+ indications, capitalizing on T‑cell engager technology (proven in oncology: Blincyto) applied to B‑cell and plasma cell‑mediated autoimmune diseases.
Capital Scale: The $700 million cash position—among the largest autoimmune biotech financings—provides runway through 2030, enabling multiple Phase 2 readouts and potential Phase 3 initiation without additional dilutive financing.
Cizutamig Differentiation:BCMA‑targeting TCE for myasthenia gravis addresses autoantibody‑producing plasma cells (not just B cells)—a deeper, more durable depletion mechanism vs. existing therapies (Soliris, Ultomiris).
Platform Breadth:CD20, BCMA, and dual‑targeting TCEs create indication‑agnostic autoimmune toolkit, applicable across SLE, MS, pemphigus, ILD, and rare autoantibody diseases.
Market Context
Factor
Impact
Autoimmune TCE Market
Emerging field; no approved TCEs for autoimmunity; Candid/Rallybio first‑mover advantage
BCMA in Autoimmunity
BCMA expressed on plasma cells (antibody factories); targeting BCMA vs. CD19/CD20 offers deeper, longer‑lasting response
Myasthenia Gravis Market
~ $1.5 billion; dominated by C5 inhibitors (Soliris, Ultomiris); TCEs offer potential functional cure via plasma cell depletion
Competitive Landscape
AbbVie, Johnson & Johnson developing TCEs for autoimmunity; Candid’s 10+ indication breadth and $700M capital create competitive moat
Forward‑Looking Statements This brief contains forward‑looking statements regarding merger closing, Phase 2 clinical outcomes, and TCE autoimmune market development. Actual results may differ due to risks including cytokine release syndrome in autoimmune populations, competitive TCE advancement, and integration execution.-Fineline Info & Tech
By Fineline Cube